Heather A. Parsons

Sep 19, 2024 | medscape.com | Kathy D. Miller |Heather A. Parsons

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Kathy D. Miller, MD: Hi, everyone. I'm Dr Kathy Miller. Welcome to the Medscape InDiscussion podcast series on breast cancer and HER2. Today, we are going to tackle the management of patients with HER2+ oligometastatic disease.

May 10, 2024 | nature.com | Filipa Lynce |Candace Mainor |Renee N Donahue |Xue Geng |Greg Jones |Ilana Schlam | +15 more

Correction to: Nature Communications https://doi.org/10.1038/s41467-024-46961-x, published online 27 March 2024The original version of the article file contained some inaccuracies in the main text. To avoid misinterpretation of the findings, the following corrections have now been made in the revised PDF and HTML versions of the article file. Abstract.

Mar 26, 2024 | nature.com | Filipa Lynce |Candace Mainor |Renee N Donahue |Xue Geng |Greg Jones |Ilana Schlam | +15 more

AbstractChemotherapy and immune checkpoint inhibitors have a role in the post-neoadjuvant setting in patients with triple-negative breast cancer (TNBC). However, the effects of nivolumab, a checkpoint inhibitor, capecitabine, or the combination in changing peripheral immunoscore (PIS) remains unclear. This open-label randomized phase II OXEL study (NCT03487666) aimed to assess the immunologic effects of nivolumab, capecitabine, or the combination in terms of the change in PIS (primary endpoint).

Jan 29, 2024 | healio.com | David Statman |Mindy Valcarcel |Heather A. Parsons

Read more You've successfully added Hematology Oncology: Breast Cancer to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected].

Dec 7, 2023 | cancernetwork.com | Heather A. Parsons

In a conversation with CancerNetwork® during the 2023 San Antonio Breast Cancer Symposium (SABCS), Heather A. Parsons, MD, MPH, discussed how the use of a liquid biopsy platform for classifying HER2 status in those with breast cancer may help with understanding a patient’s disease and predict what therapies they may respond to.